Baylor Scott & White Health, Temple, TX, USA.
Pfizer Inc., New York, NY, USA.
Am J Health Syst Pharm. 2023 Dec 5;80(24):1830-1839. doi: 10.1093/ajhp/zxad188.
To measure the effect of clinical decision support (CDS) on anticoagulation rates in patients with atrial fibrillation (AFib) or atrial flutter (AFlut) at high stroke risk and receiving care in outpatient settings, and to assess provider response to CDS.
This observational, quasi-experimental, interrupted time series study utilized electronic health record data at a large integrated delivery network in Texas from April to November 2020. CDS consisted of an electronic Best Practice Advisory (BPA)/alert (Epic Systems Corporation, Verona, WI) with links to 2 AFib order sets displayed to providers in outpatient settings caring for non-anticoagulated patients with AFib and elevated CHA2DS2VASc scores. Weekly outpatient anticoagulation rates were assessed in patients with high stroke risk before and after implementation of CDS. Alert actions and acknowledgment reasons were evaluated descriptively.
Mean (SD) weekly counts of eligible patients were 8,917 (566) before and 8,881 (811) after implementation. Weekly anticoagulation rates increased during the pre-BPA study period (β1 = 0.07%; SE, 0.02%; P = 0.0062); however, there were no significant changes in the level (β2 = 0.60%; SE, 0.42%; P = 0.1651) or trend (β3 = -0.01%; SE, 0.05%; P = 0.8256) of anticoagulation rates associated with CDS implementation. In encounters with the BPA/alert displayed (n = 17,654), acknowledgment reasons were provided in 4,473 (25.3%) of the encounters, with prescribers most commonly citing bleeding risk (n = 1,327, 7.5%) and fall risk (n = 855, 4.8%).
There was a significant trend of increasing anticoagulation rates during the pre-BPA period, with no significant change in trend during the post-BPA period relative to the pre-BPA period.
测量临床决策支持(CDS)对高卒中风险的房颤(AFib)或房扑(AFlut)患者在门诊环境中接受抗凝治疗的影响,并评估提供者对 CDS 的反应。
这是一项在德克萨斯州一家大型综合医疗服务网络进行的观察性、准实验性、中断时间序列研究,利用了 2020 年 4 月至 11 月期间的电子健康记录数据。CDS 由一个电子最佳实践咨询(BPA)/警报(Epic Systems Corporation,威斯康星州 Verona)组成,该警报与两个房颤医嘱集链接,显示给在门诊环境中照顾非抗凝治疗、CHADS2VASc 评分升高的房颤患者的提供者。在实施 CDS 前后,评估高卒中风险患者的每周门诊抗凝治疗率。描述性评估了警报动作和确认原因。
在实施 BPA 之前,每周符合条件的患者人数为 8917(566),实施后为 8881(811)。在 BPA 研究期间,每周抗凝治疗率增加(β1=0.07%;SE,0.02%;P=0.0062);然而,与 CDS 实施相关的抗凝治疗率的水平(β2=0.60%;SE,0.42%;P=0.1651)或趋势(β3=-0.01%;SE,0.05%;P=0.8256)均无显著变化。在显示 BPA/警报的就诊中(n=17654),在 4473(25.3%)次就诊中提供了确认原因,最常见的原因是出血风险(n=1327,7.5%)和跌倒风险(n=855,4.8%)。
在 BPA 之前的时期,抗凝治疗率有显著的上升趋势,但与 BPA 之前的时期相比,BPA 之后的时期没有显著的变化趋势。